Clinical Trial Update: Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update for a Phase 2/3 study evaluating docetaxel with or without oblimersen (Genasense) in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Genasense (oblimersen)

Snippet

Sponsor: Genta Incorporated | Conditions: Lung Cancer | Phase 2, Phase 3 | Status: UNKNOWN